Jonathan Gelfond1, Kara Choate2, Donna P Ankerst3, Javier Hernandez4, Robin J Leach5, Ian M Thompson6. 1. Department of Biostatistics and Epidemiology, University of Texas Health Science Center at San Antonio, San Antonio, Texas; Department of Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas. 2. Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas. 3. Department of Biostatistics and Epidemiology, University of Texas Health Science Center at San Antonio, San Antonio, Texas; Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas; Department of Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas. 4. Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas; Department of Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas. 5. Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas; Department of Cellular and Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, Texas; Department of Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas. 6. Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas; Department of Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas. Electronic address: thompsoni@uthscsa.edu.
Abstract
PURPOSE: Prostate specific antigen screening is controversial, as a large number of men must be screened annually to achieve a benefit. We sought to determine whether baseline prostate specific antigen could reliably predict subsequent risk of prostate cancer and risk of consequential prostate cancer. MATERIALS AND METHODS: A multiethnic cohort of 2,923 prostate cancer-free men was recruited between 2000 and 2012, and followed for a median of 7.5 years. Baseline prostate specific antigen was stratified into 6 strata and relative hazards of prostate cancer detection for each prostate specific antigen stratum were estimated, adjusting for ethnicity, family history and age. RESULTS: During followup 289 patients were diagnosed with prostate cancer. Men with baseline prostate specific antigen in the lowest stratum (0.1 to 1.0 ng/ml) were at greatly reduced risk for prostate cancer during followup. This half of the cohort with prostate specific antigen 1.0 ng/ml or less were at 3.4% (95% CI 2.1, 4.5) 10-year risk of prostate cancer and 90% of the cancers were low risk. By comparison the other half were at 15% to 39% risk of cancer detection with a 39% risk in the highest stratum (3 to 10 ng/ml). CONCLUSIONS: Optimal prostate specific antigen screening frequency for men with a prostate specific antigen level of 0.1 to 1.0 ng/ml may be up to every 10 years. This approach has the potential to dramatically reduce the cost of screening, decreasing over detection of inconsequential tumors, while maintaining detection of tumors for which treatment has been proven to reduce prostate cancer mortality.
PURPOSE:Prostate specific antigen screening is controversial, as a large number of men must be screened annually to achieve a benefit. We sought to determine whether baseline prostate specific antigen could reliably predict subsequent risk of prostate cancer and risk of consequential prostate cancer. MATERIALS AND METHODS: A multiethnic cohort of 2,923 prostate cancer-free men was recruited between 2000 and 2012, and followed for a median of 7.5 years. Baseline prostate specific antigen was stratified into 6 strata and relative hazards of prostate cancer detection for each prostate specific antigen stratum were estimated, adjusting for ethnicity, family history and age. RESULTS: During followup 289 patients were diagnosed with prostate cancer. Men with baseline prostate specific antigen in the lowest stratum (0.1 to 1.0 ng/ml) were at greatly reduced risk for prostate cancer during followup. This half of the cohort with prostate specific antigen 1.0 ng/ml or less were at 3.4% (95% CI 2.1, 4.5) 10-year risk of prostate cancer and 90% of the cancers were low risk. By comparison the other half were at 15% to 39% risk of cancer detection with a 39% risk in the highest stratum (3 to 10 ng/ml). CONCLUSIONS: Optimal prostate specific antigen screening frequency for men with a prostate specific antigen level of 0.1 to 1.0 ng/ml may be up to every 10 years. This approach has the potential to dramatically reduce the cost of screening, decreasing over detection of inconsequential tumors, while maintaining detection of tumors for which treatment has been proven to reduce prostate cancer mortality.
Authors: Ricardo A Rendon; Ross J Mason; Karim Marzouk; Antonio Finelli; Fred Saad; Alan So; Phillipe Violette; Rodney H Breau Journal: Can Urol Assoc J Date: 2017-10 Impact factor: 1.862
Authors: Ross J Mason; Karim Marzouk; Antonio Finelli; Fred Saad; Alan I So; Philippe D Violette; Rodney H Breau; Ricardo A Rendon Journal: Can Urol Assoc J Date: 2022-04 Impact factor: 2.052
Authors: Jonathan A Gelfond; Brian Hernandez; Martin Goros; Joseph G Ibrahim; Ming-Hui Chen; Wei Sun; Robin J Leach; Michael W Kattan; Ian M Thompson; Donna Pauler Ankerst; Michael Liss Journal: BMC Urol Date: 2022-03-26 Impact factor: 2.090
Authors: E David Crawford; Matt T Rosenberg; Alan W Partin; Matthew R Cooperberg; Michael Maccini; Stacy Loeb; Curtis A Pettaway; Neal D Shore; Paul Arangua; John Hoenemeyer; Mike Leveridge; Michael Leapman; Peter Pinto; Ian M Thompson; Peter Carroll; James Eastham; Leonard Gomella; Eric A Klein Journal: Urology Date: 2016-07-19 Impact factor: 2.649
Authors: Richard J Rebello; Christoph Oing; Karen E Knudsen; Stacy Loeb; David C Johnson; Robert E Reiter; Silke Gillessen; Theodorus Van der Kwast; Robert G Bristow Journal: Nat Rev Dis Primers Date: 2021-02-04 Impact factor: 52.329
Authors: Eveline A M Heijnsdijk; Roman Gulati; Alex Tsodikov; Jane M Lange; Angela B Mariotto; Andrew J Vickers; Sigrid V Carlsson; Ruth Etzioni Journal: J Natl Cancer Inst Date: 2020-10-01 Impact factor: 13.506